NEW YORK, Dec. 6, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors can obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/agio.
The investigation concerns whether Agios and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
At the 2016 American Society of Hematology meeting (December 3-6, 2016), Agios showed its new data for its AG-348 and AG-519 molecules, for treatment of pyruvate kinase deficiency. Agios specified that a case of Grade 2 thrombocytopenia (a reduction of platelets in blood cells) was reported in a patient receiving AG-519, and that an ongoing severe adverse event of drug-related cholestatic hepatitis was seen in a bioavailability and food effect study after a dose of 300 mg. Following this news, Agios stock dropped as much $9.03, or 15.85%, to $47.94 on December 5, 2016.
If you are aware of any facts relating to this investigation, or purchased Agios shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/agio. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-agios-pharmaceuticals-inc-agio-300373588.html
SOURCE Bronstein, Gewirtz & Grossman, LLC